Quantcast

Industry news that matters to you.  Learn more

GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to an Innovative Diagnostic Assay for Non-Alcoholic Steatohepatitis (NASH)

LabCorp, a leading global life sciences company, and GENFIT, a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, have announced the signing of a licensing agreement between GENFIT and Covance, LabCorp’s drug development business. The agreement will expand access to an innovative non-alcoholic steatohepatitis (NASH) liver diagnostic test for the clinical research market.

Singapore Scientists Develop New DNA Technology to Detect Breast Cancer Relapse

Researchers in Singapore, together with international collaborators from Denmark and USA, have successfully identified a unique biomarker that is strongly associated with breast cancer relapse. This finding has led to the development of a simple blood test which has numerous clinical applications, such as detecting relapse early and testing treatment efficacy. The study was recently published in scientific journal Nature Medicine in September 2017.

200 Million Americans Now Have Insurance Coverage for Biodesix’s VeriStrat Test; BCBS of FLorida and Health Services Corporation Issue Positive Coverage Decisions

VeriStrat®, Biodesix’ proteomic blood test for patients with advanced NSCLC, has received multiple positive coverage decisions in 2016. As a result, 200 million Americans now have insurance coverage for VeriStrat. The most recent positive coverage decisions include BlueCross BlueShield (BCBS) of Florida and Health Care Services Corporation (HCSC).

NUS Scientists a Step Closer to Developing Blood Test to Monitor Status of Cancer and Treatment Outcome

Scientists from the National University of Singapore (NUS) have developed a novel technique to efficiently culture clusters containing circulating tumour cells (CTCs) in 14 days that could be used to predict the outcome of cancer treatment as well as monitor the status of cancer. Using the technique, the team achieved a success rate of more than 60 per cent in culturing CTCs from patients with metastatic breast cancer, the highest known success record to-date. This breakthrough brings researchers a step closer towards enabling personalised cancer treatment and monitoring.

A Biomarker for Premature Death

A single blood test could reveal whether an otherwise healthy person is unusually likely to die of pneumonia or sepsis within the next 14 years. Based on an analysis of 10,000 individuals, researchers have identified a molecular byproduct of inflammation, called GlycA, which seems to predict premature death due to infections.